Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction

Pediatrics

Volumn 130, Issue 2, 2012, Pages

  Kahn, Jessica A ^a   Brown, Darron R ^b   Ding, Lili ^a   Widdice, Lea E ^a   Shew, Marcia L ^b   Glynn, Susan ^a   Bernstein, David I ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; Herd protection; Human papillomavirus vaccines; Prevalence

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; COVARIANCE; DISEASE SURVEILLANCE; DNA DETERMINATION; EVIDENCE BASED MEDICINE; FEMALE; HERD IMMUNITY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POSTMARKETING SURVEILLANCE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SEXUAL INTERCOURSE; VACCINATION; VIRUS TYPING; WART VIRUS;

EID: 84864528970     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3587     Document Type: Article

References (40)

1. Harper DM, Franco EL, Wheeler CM, et al; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255
2. Koutsky LA; FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927
3. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943
4. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629
5. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630-632
6. Freeman HP, Wingrove BK. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. NIH publication no. 05-5282. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005
7. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007;110(1):87-95 (Pubitemid 47015705)
8. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(suppl 1):S97-S106 (Pubitemid 40144234)
9. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28(30):4731-4737
10. Hildesheim A, Herrero R, Wacholder S, et al Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-753 (Pubitemid 47263157)
11. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet. 1996;348(9022):271-272
12. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180(4):1171-1176 (Pubitemid 30070201)
13. Eskola J, Kilpi T, Palmu A, et al Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403-409 (Pubitemid 32128672)
14. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis. 2004;39(7):930-938 (Pubitemid 39313446)
15. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192(11):1988-1995 (Pubitemid 41681898)
16. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics. 2005;116(3). Available at: www.pediatrics.org/cgi/content/full/116/3/e408
17. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr U.S. Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J. 2006;25(4):301-305
18. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(suppl3):S3/106-S3/113
19. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol. 2008;111(5):1103-1110 (Pubitemid 351620344)
20. Shikary T, Bernstein DI, Jin Y, Zimet GD, Rosenthal SL, Kahn JA. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol. 2009;46(2):107-111
21. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361 (Pubitemid 30043317)
22. Ermel A, Qadadri B, Morishita A, et al. Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay. J Virol Methods. 2010;169(1):154-161
23. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424
24. Bouvard V, Baan R, Straif K, et al WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens - Part B: biological agents. Lancet Oncol. 2009;10(4):321-322
25. Gottlieb SL, Brewer NT, Sternberg MR, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health. 2009;45(5):430-437
26. Wong CA, Berkowitz Z, Dorell CG, Anhang Price R, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008. Cancer. 2011;117(24):5612-5620
27. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004;189(1):46-50 (Pubitemid 38122328)
28. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191(2):182-192 (Pubitemid 40096375)
29. Porras C, Rodríguez AC, Hildesheim A, et al. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev. 2009;18(3):863-865
30. Bosch FX, de Sanjose S. Future Directions in Epidemiologic and Preventive Research on Human Papillomaviruses and Cancer. Bethesda, MD: Oxford University Press; 2003:3-13
31. Abramowitz L, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer. 2011;129(2):433-439
32. Kretzschmar M. Sexual network structure and sexually transmitted disease prevention: a modeling perspective. Sex Transm Dis. 2000;27(10):627-635
33. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-1708
34. Leiner S. HPV vaccination. N Engl J Med. 2009;361(16):1610-1611, author reply 1610-1611
35. Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD. Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol. 2009;83(3):1443-1455
36. Plummer M, Schiffman M, Castle PE, Maucort- Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582-1589 (Pubitemid 46799215)
37. Kaasila M, Koskela P, Kirnbauer R, Pukkala E, Surcel HM, Lehtinen M. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer. 2009;125(9):2166-2172
38. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-935
39. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36(10):3020-3027 (Pubitemid 28429431)
40. Steinau M, Swan DC, Unger ER. Type-specific reproducibility of the Roche linear array HPV genotyping test. J Clin Virol. 2008;42(4):412-414